Novartis Paying $75M Up Front
Portola's Anticlotting Drug Gains Partner in Potential $575M Deal
In its first major collaboration, privately held Portola Pharmaceuticals Inc. partnered one of its two lead antithrombotic programs with Novartis AG in a deal potentially worth up to $575 million. (BioWorld Today)
